A Randomized, Double-Blind, Phase 2 Study of Erlotinib (Tarceva) in Combination With OSI-906 or Placebo in Chemonaive Patients With Advanced NSCLC With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene.
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2014
At a glance
- Drugs Linsitinib (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Astellas Pharma
- 12 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Aug 2014 Planned End Date changed from 1 Jul 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.
- 12 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.